BACKGROUND: Drug resistance testing and co-receptor tropism determination are key components of the management of antiretroviral therapy for HIV-1-infected individuals. The purpose of this study was to examine trends of HIV-1 resistance and viral evolution in the past decade by surveying a large commercial patient testing database. METHODS: Temporal trends of drug resistance, viral fitness and co-receptor usage among samples submitted for routine phenotypic and genotypic resistance testing to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), as well as for tropism determination were investigated. RESULTS: Within 62,397 resistant viruses reported from 2003 to 2012, we observed a decreasing trend in the prevalence of three-class resistance (from 25% to 9%) driven by decreased resistance to PIs (43% to 21%) and NRTIs (79% to 57%), while observing a slight increase in NNRTI resistance (68% to 75%). The prevalence of CXCR4-mediated entry among tropism testing samples (n=52,945) declined over time from 47% in 2007 to 40% in 2012. A higher proportion of CXCR4-tropic viruses was observed within samples with three-class resistance (50%) compared with the group with no resistance (36%). CONCLUSIONS: Decreased prevalence of three-class resistance and increased prevalence of one-class resistance was observed within samples reported between 2003 and 2012. The fraction of CXCR4-tropic viruses has decreased over time; however, CXCR4 usage was more prevalent among multi-class-resistant samples, which may be due to the more advanced disease stage of treatment-experienced patients. These trends have important implications for clinical practice and future drug discovery and development.
BACKGROUND: Drug resistance testing and co-receptor tropism determination are key components of the management of antiretroviral therapy for HIV-1-infected individuals. The purpose of this study was to examine trends of HIV-1 resistance and viral evolution in the past decade by surveying a large commercial patient testing database. METHODS: Temporal trends of drug resistance, viral fitness and co-receptor usage among samples submitted for routine phenotypic and genotypic resistance testing to protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), as well as for tropism determination were investigated. RESULTS: Within 62,397 resistant viruses reported from 2003 to 2012, we observed a decreasing trend in the prevalence of three-class resistance (from 25% to 9%) driven by decreased resistance to PIs (43% to 21%) and NRTIs (79% to 57%), while observing a slight increase in NNRTI resistance (68% to 75%). The prevalence of CXCR4-mediated entry among tropism testing samples (n=52,945) declined over time from 47% in 2007 to 40% in 2012. A higher proportion of CXCR4-tropic viruses was observed within samples with three-class resistance (50%) compared with the group with no resistance (36%). CONCLUSIONS: Decreased prevalence of three-class resistance and increased prevalence of one-class resistance was observed within samples reported between 2003 and 2012. The fraction of CXCR4-tropic viruses has decreased over time; however, CXCR4 usage was more prevalent among multi-class-resistant samples, which may be due to the more advanced disease stage of treatment-experienced patients. These trends have important implications for clinical practice and future drug discovery and development.
Authors: Katherine E Kupiec; James W Johnson; Luis F Barroso; Rebekah H Wrenn; John C Williamson Journal: AIDS Patient Care STDS Date: 2014-11 Impact factor: 5.078
Authors: Jessie K Edwards; Stephen R Cole; Jeffrey N Martin; Richard Moore; W Christopher Mathews; Mari Kitahata; Joseph J Eron; Michael Saag; Michael J Mugavero Journal: Clin Infect Dis Date: 2015-04-01 Impact factor: 9.079
Authors: Iris Chen; Matthew B Connor; William Clarke; Mark A Marzinke; Vanessa Cummings; Autumn Breaud; Jessica M Fogel; Oliver Laeyendecker; Sheldon D Fields; Deborah Donnell; Sam Griffith; Hyman M Scott; Steven Shoptaw; Carlos del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Lucia R I Millham; Justine A Scott; Paul E Sax; Fatma M Shebl; Krishna P Reddy; Elena Losina; Rochelle P Walensky; Kenneth A Freedberg Journal: J Acquir Immune Defic Syndr Date: 2020-02-01 Impact factor: 3.771
Authors: Juan J Calva; Juan Sierra-Madero; Luis E Soto-Ramírez; Pedro Aguilar-Salinas Journal: Open Forum Infect Dis Date: 2014-09-10 Impact factor: 3.835
Authors: Kristina L Bajema; Robin M Nance; Joseph A C Delaney; Ellen Eaton; Thibaut Davy-Mendez; Maile Y Karris; Richard D Moore; Joseph J Eron; Benigno Rodriguez; Kenneth H Mayer; Elvin Geng; Cindy Garris; Michael S Saag; Heidi M Crane; Mari M Kitahata Journal: AIDS Date: 2020-11-15 Impact factor: 4.632